ASH 2022 Conference Coverage

 

ASH 2022 Conference Coverage
Avatar

ASH 2022 Outcomes of Penta-Refractory MM Patients Based on Access to BCMA-Directed Therapy

By ASH 2022 Conference Coverage FEATURING Shebli Atrash
By ASH 2022 Conference Coverage FEATURING Shebli Atrash
129 views
December 19, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Myeloma
07:05
ASH 2022 Conference Coverage

ASH 2022 Phase 1/2 Results From MonumenTAL-1: Talquetamab, a G Prote…

Feat. A. Chari
07:25
ASH 2022 Conference Coverage

ASH 2022 Results of the ASCENT Trial: Fixed Duration Therapy With Da…

Feat. S. Kumar
10:37
ASH 2022 Conference Coverage

ASH 2022 Mezigdomide (CC-92480) + Dex in R/R MM: Preliminary Results…

Feat. P. Richardson
24:01
ASH 2022 Conference Coverage

ASH 2022: First Relapse in Multiple Myeloma - How to Pick the Next B…

Feat. Y. Efebera
07:37
ASH 2022 Conference Coverage

IKEMA Subgroup Analysis: Isatuximab + Carfilzomib & Dexamethason…

Feat. T. Martin
10:37
ASH 2022 Conference Coverage

ASH 2022 Subsequent Antimyeloma Therapies From ICARIA-MM Study: Pom/…

Feat. P. Richardson
06:25
ASH 2022 Conference Coverage

ASH 2022 Phase 3 EMagine/CARTITUDE-6 Trial: DVRd Followed by either …

Feat. P. Sonneveld
11:25
ASH 2022 Conference Coverage

ASH 2022 MAIA Trial Age Subgroup Analysis: Daratumumab + Lenalidomid…

Feat. T. Plesner
15:03
ASH 2022 Conference Coverage

ASH 2022: A Consultant’s Guide to Smoldering Multiple Myeloma

Feat. S. Thorsteinsdottir
04:10
ASH 2022 Conference Coverage

ASH 2022 SubQ Isatuximab + Carfilzomib & Dexamethasone in Relaps…

Feat. H. Quach
20:46
ASH 2022 Conference Coverage

ASH 2022 Understanding and Monitoring Resistance to Anti-CD38 and -B…

Feat. F. Pichiorri
11:12
ASH 2022 Conference Coverage

ASH 2022 Gene Edited Off-the-Shelf NK Cells for Treating Hematologic…

Feat. J. Miller
05:18
ASH 2022 Conference Coverage

ASH 2022 Phase II DEDALO Trial: Daratumumab + Pomalidomide & Dex…

Feat. V. Montefusco
14:16
ASH 2022 Conference Coverage

Assessing Disease Risk in Multiple Myeloma: High or Low?

Feat. T. Schmidt
03:00
ASH 2022 Conference Coverage

ASH 2022 Phase 1 MagnetisMM-1 Trial: Elranatamab, a BCMA Targeted T-…

Feat. N. S. Raje
06:16
ASH 2022 Conference Coverage

U.S. Myeloma CAR-T Consortium Real World Experience: Factors Associa…

Feat. H. Hashmi
08:24
ASH 2022 Conference Coverage

ASH 2022 Once Weekly Selinexor, Carfilzomib & Dexamethasone (XKd…

Feat. G. Schiller
10:08
ASH 2022 Conference Coverage

ASH 2022 Maintenance Therapy Cessation for Sustained MRD Negative MM…

Feat. N. Korde
10:34
ASH 2022 Conference Coverage

ASH 2022 Phase 1/2 LINKER-MM1 Study of Linvoseltamab, a BCMAxCD3 Bis…

Feat. N. Bumma
07:17
ASH 2022 Conference Coverage

ASH 2022 Phase 3 VITAL Study: Survival Benefit of Birtamimab in Mayo…

Feat. M. Gertz
05:05
ASH 2022 Conference Coverage

ASH 2022 Outcomes of Penta-Refractory MM Patients Based on Access to…

Feat. S. Atrash
15:32
ASH 2022 Conference Coverage

Novel Approaches to Myeloma Burden Assessment

Feat. T. Kourelis
14:03
ASH 2022 Conference Coverage

ASH 2022 Neurotoxicity With Motor Symptoms After BCMA-Directed CAR-T…

Feat. S. Parekh
05:56
ASH 2022 Conference Coverage

ASH 2022 Myeloma XI Trial: Defining the Optimal Duration of Lenalido…

Feat. G. Morgan
14:23
ASH 2022 Conference Coverage

ASH 2022 Phase I Dose-Escalation Study of Forimtamig (RG6234), a GPR…

Feat. C. Carlo-Stella
04:31
ASH 2022 Conference Coverage

ASH 2022 GRIFFIN Trial Final Analysis: D-RVd in Clinically Relevant …

Feat. A. Chari